StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)

Close on Nov 17, 2026Market cap $1.70BP/E –Yield –

Stoke Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Stoke Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$177.99M, down 389.0% year over year. For fiscal 2025 it was $45.59M. The highest annual figure on record is $45.59M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$45.59M–
FY2024Dec 31, 2024-$86.85M–
FY2023Dec 31, 2023-$81.07M–
FY2022Dec 31, 2022-$31.87M–
FY2021Dec 31, 2021-$66.91M–
FY2020Dec 31, 2020-$42.22M–
FY2019Dec 31, 2019-$31.06M–
FY2018Dec 31, 2018-$10.96M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$56.59M–
Q1 FY2026Mar 31, 2026-$60.58M-146.0%
Q4 FY2025Dec 31, 2025-$30.45M–
Q3 FY2025Sep 30, 2025-$30.37M–
Q2 FY2025Jun 30, 2025-$25.42M–
Q1 FY2025Mar 31, 2025$131.83M–
Q4 FY2024Dec 31, 2024-$23.19M–
Q3 FY2024Sep 30, 2024-$21.62M–
Q2 FY2024Jun 30, 2024-$17.48M–
Q1 FY2024Mar 31, 2024-$24.57M–
Q4 FY2023Dec 31, 2023-$20.65M–
Q3 FY2023Sep 30, 2023-$17.26M–
Q2 FY2023Jun 30, 2023-$21.80M–
Q1 FY2023Mar 31, 2023-$21.36M-165.7%
Q4 FY2022Dec 31, 2022-$22.37M–
Q3 FY2022Sep 30, 2022-$22.06M–
Q2 FY2022Jun 30, 2022-$19.93M–
Q1 FY2022Mar 31, 2022$32.49M–
Q4 FY2021Dec 31, 2021-$16.26M–
Q3 FY2021Sep 30, 2021-$14.68M–
Q2 FY2021Jun 30, 2021-$15.83M–
Q1 FY2021Mar 31, 2021-$20.14M–
Q4 FY2020Dec 31, 2020-$10.93M–
Q3 FY2020Sep 30, 2020-$10.87M–
Q2 FY2020Jun 30, 2020-$9.65M–
Q1 FY2020Mar 31, 2020-$10.77M–
Q4 FY2019Dec 31, 2019-$10.20M–
Q3 FY2019Sep 30, 2019-$8.05M–
Q2 FY2019Jun 30, 2019-$6.27M–
Q1 FY2019Mar 31, 2019-$6.53M–
Q4 FY2018Dec 31, 2018-$3.52M–
Q3 FY2018Sep 30, 2018-$3.04M–

More Stoke Therapeutics figures

See a number that looks wrong?